Stabilized GHRH · FDA approved.
Tesamorelin is a synthetic GHRH analog stabilized against DPP-4 cleavage by an N-terminal hexenoyl modification. It is FDA-approved (as Egrifta) for the treatment of HIV-associated lipodystrophy — one of the few GH-related peptides with a specific approved indication. Supplied as research-grade material with 3rd-party HPLC verification and full Certificate of Analysis per lot.
Tesamorelin is a synthetic GHRH analog stabilized against DPP-4 cleavage by an N-terminal hexenoyl modification. It is FDA-approved (as Egrifta) for the treatment of HIV-associated lipodystrophy — one of the few GH-related peptides with a specific approved indication.
Binds the GHRH receptor to stimulate endogenous pulsatile GH release. The N-terminal trans-3-hexenoyl modification blocks DPP-4 mediated cleavage between Tyr¹ and Ala², extending plasma half-life roughly 10-fold compared to native GHRH.
FDA-approved as Egrifta (Theratechnologies, 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Listed in the WADA prohibited list.
The above summarizes published research literature. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.
Tesamorelin is a 44-residue peptide with molecular formula C221H366N72O67S and molecular weight of approximately 5,135.9 Da.
The full structural data and release specifications are in the Compound Profile section above. Every lot ships with an independently verified Certificate of Analysis.
Each lot is independently verified by a 3rd-party analytical laboratory (STERIS Labs, Alcami Analytical, or equivalent) before release. Release specification is HPLC purity ≥ 99.5% (typical > 99.8%), mass spectrometry identity match within ±0.5 Da, water content < 5.0% Karl Fischer, and endotoxin < 0.25 EU/mL by LAL (USP <85>).
Look up the full COA for your lot at coa-lookup.html.
All compounds ship at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way. Tracked; signature not required.
Store unopened lyophilized product at 2–8°C protected from light. Once reconstituted, most peptides are stable at 2–8°C for approximately 28 days (compound-dependent).
FDA-approved as Egrifta (Theratechnologies, 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Listed in the WADA prohibited list.
All PeptideBros compounds are sold strictly as chemical reference materials for in-vitro laboratory research. They are not for human consumption.
HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.